Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a natural protein help control blood sugar in type 2 diabetes?

NCT ID NCT02724566

Disease control Sponsor: University Hospital, Toulouse Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study tested whether a protein called apelin can improve how the body uses insulin in people with type 2 diabetes. Nine volunteers received both apelin and a placebo infusion to compare effects. The goal was to see if apelin increases the amount of sugar the body can process, which could lead to better blood sugar control.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
apelin (a synthetic version of a natural protein, given as an infusion)
What this could lead to
If it works, this could point toward a new way to improve insulin sensitivity in type 2 diabetes.
What could go wrong
This is a very small, early-phase trial with only 9 participants. It is designed to test safety and basic effects, not to prove a treatment works.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

9 people

The number who actually took part.

Started

May 2016

Finished

Apr 2017

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 65 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Clinical diagnosis of type2 diabetes * Body Mass Index between 27 and 33 kg / cm ² * HbA1c \< 8.5% * Non-pathological Electrocardiogram * Heart rate between 50 and 80 beats per minute at rest. * Complete Blood Count (CBC) with no significant anomaly in terms of the investigator.. * Serum electrolytes without clinically significant abnormalities in terms of the investigator. * Liver function tests without clinically significant abnormalities in terms of the investigator * Renal function tests without clinically significant abnormalities in terms of the investigator * Good peripheral vein (forearm and back of the hand). * Agreement to participate in the establishment of a serum bank. * Ability to sign informed consent. * Affiliation to a social security scheme Exclusion Criteria: * Secondary prevention of cardio-vascular disease * Insulin therapy or Glucagon Like Peptid 1 (GLP-1) analogs therapy in the 6 months before inclusion. * Risk factor, treatment or electrocardiogram as recommended by International Conference on Harmonization (ICH) E14 "Clinical Evaluation of QT / QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs" * Repeated a QTc interval\> 450 ms measurement * Risk factor for torsade de pointes: myocardial infarction, hypokalemia, family history of long QT syndrome * Personal history of cancer. * Positive HIV serology. * Hepatitis B serology positive. * Positive hepatitis C serology. * Cognitive impairment or mental illness (at the discretion of the investigator). * Chronic excessive alcohol consumption (consumption \> 30g/day or 210g/week). * Person under judicial protection, guardianship. * Subject with a resting systolic blood pressure greater than 140 mm Hg and diastolic blood pressure greater than 90 mmHg * Smoking more than 10 cigaret per day and can not be interrupted for 24 hours.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetes mellitus type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes

Contacts and locations

Locations

  • University Hospitals of Toulouse (Rangueil)

    Toulouse, Midi-Pyrénées, 31059, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.